ALX Oncology Holdings Inc.
$1.75
▼
-0.51%
2026-04-21 05:15:01
www.alxoncology.com
NMS: ALXO
Explore ALX Oncology Holdings Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$219.79 M
Current Price
$1.75
52W High / Low
$2.66 / $0.4
Stock P/E
—
Book Value
$0.48
Dividend Yield
—
ROCE
-292.37%
ROE
-1.46%
Face Value
—
EPS
$-1.9
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
43
Beta
0.5
Debt / Equity
56.85
Current Ratio
2.07
Quick Ratio
2.07
Forward P/E
-2.77
Price / Sales
—
Enterprise Value
$193.71 M
EV / EBITDA
-1.93
EV / Revenue
—
Rating
None
Target Price
$4.6
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Krystal Biotech, Inc. | $276.4 | 40.42 | $8.11 B | — | 13.1% | 18.91% | $298.3 / $122.8 | $41.78 |
| 2. | Lantern Pharma Inc. | $2.76 | — | $27.91 M | — | -275.14% | -1.24% | $5.74 / $1.11 | $0.58 |
| 3. | Jyong Biotech Ltd. | $2.31 | — | $185.51 M | — | 35.69% | 8.55% | $67 / $1.43 | $-0.31 |
| 4. | Orchestra BioMed Holdings, Inc. | $4.35 | — | $268.03 M | — | -52.8% | -1.09% | $5.42 / $2.2 | $0.94 |
| 5. | Atossa Therapeutics, Inc. | $6.17 | — | $50.2 M | — | -94.38% | -62.74% | $19.35 / $3.76 | $4.57 |
| 6. | Regeneron Pharmaceuticals, Inc. | $753.59 | 17.99 | $79.36 B | 0.5% | 10.23% | 14.86% | $821.11 / $476.49 | $304.65 |
| 7. | Tonix Pharmaceuticals Holding Corp. | $14.34 | — | $184.59 M | — | -49.81% | -64.48% | $69.97 / $11.6 | $19.17 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -23.02 M | -22.53 M | -23.47 M | -31.82 M | -30.61 M | — |
| Net Profit | -22.85 M | -22.14 M | -25.95 M | -30.75 M | -29.16 M | — |
| EPS in Rs | -0.17 | -0.17 | -0.2 | -0.23 | -0.22 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -100.85 M | -142.47 M | -170.28 M | -127.44 M |
| Net Profit | -101.69 M | -134.85 M | -160.81 M | -123.48 M |
| EPS in Rs | -0.77 | -1.02 | -1.22 | -0.94 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 59.05 M | 147.78 M | 242.55 M | 306.49 M |
| Total Liabilities | 33.06 M | 34.16 M | 52.84 M | 43.02 M |
| Equity | 25.98 M | 113.62 M | 189.71 M | 263.46 M |
| Current Assets | 50.73 M | 134.35 M | 188.66 M | 270.97 M |
| Current Liabilities | 24.55 M | 18.5 M | 36 M | 28.32 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -84.14 M | -121.91 M | -130.36 M | -89.22 M |
| Investing CF | 82.59 M | 86.26 M | 44.66 M | -235.42 M |
| Financing CF | 0.36 M | 30.82 M | 59.29 M | 9.86 M |
| Free CF | -84.35 M | -122.36 M | -131.64 M | -90.65 M |
| Capex | -0.21 M | -0.45 M | -1.27 M | -1.43 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 16.14% | -30.23% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.